| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Neodiosgenin targets the liver X receptor (LXR), a nuclear receptor that regulates lipid metabolism and cholesterol homeostasis. LXR activation promotes fatty acid synthesis and triglyceride accumulation. By antagonizing LXR activation, Neodiosgenin suppresses fatty acid synthesis gene expression. This leads to reduced triglyceride accumulation in hepatocytes. The compound also has diverse biological activities including inhibition of LXRα and LXRβ activation induced by T0901317.
|
|---|---|
| ln Vitro |
In vitro, Neodiosgenin antagonizes LXR activation in luciferase ligand assays. It inhibits fatty acid synthesis gene expression in HepG2 hepatocytes. The compound suppresses triacylglycerol (TG) accumulation. It is a diastereomer of diosgenin with distinct biological activities. Detailed in vitro data are available in the primary literature. Neodiosgenin is a valuable tool for studying LXR function in lipid metabolism.
|
| ln Vivo |
In vivo data for Neodiosgenin are limited in publicly available sources. Based on its in vitro LXR antagonism and effects on lipid metabolism, the compound is expected to be useful for in vivo studies of lipid regulation and metabolic disorders. Further studies are needed to fully characterize its in vivo efficacy and pharmacokinetic profile. The compound is a natural product with research applications.
|
| Enzyme Assay |
In vitro LXR antagonism assays for Neodiosgenin typically use luciferase reporter assays. Cells (e.g., HEK-293) are transfected with LXR expression plasmid and LXR-responsive luciferase reporter. Cells are seeded in 96-well plates and treated with Neodiosgenin at various concentrations (0.1-100 μM) in the presence of LXR agonist (e.g., T0901317) for 24 hours. Luciferase activity is measured. IC₅₀ values for antagonism are calculated from dose-response curves. Fatty acid synthesis gene expression is measured by RT-PCR. Triglyceride accumulation is assessed by colorimetric assays or Oil Red O staining. Controls include vehicle and known LXR antagonists.
|
| Cell Assay |
For cell-based assays, HepG2 hepatocytes are cultured in DMEM with 10% FBS. Cells are seeded in 96-well plates and treated with Neodiosgenin at various concentrations (0.1-100 μM) for 24-48 hours. Fatty acid synthesis gene expression (e.g., FASN, SCD1) is analyzed by RT-PCR. Triglyceride levels are measured by colorimetric assay or Oil Red O staining. Cell viability is assessed by MTT or CellTiter-Glo. All treatments include vehicle controls and are performed in triplicate.
|
| Animal Protocol |
In vivo, Neodiosgenin may be administered to rodents via oral or intraperitoneal routes. The compound is formulated in a suitable vehicle such as DMSO, PEG, or saline-based solutions. For metabolic disease models (e.g., high-fat diet-induced obesity, NAFLD), animals are dosed at various regimens. Endpoints include serum lipid profiles, liver triglyceride content, and histology. Gene expression in liver tissue is analyzed by RT-PCR. All procedures follow institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Neodiosgenin (Yamogenin, MW 414.62, C₂₇H₄₂O₃) is a steroidal sapogenin. It is a diastereomer of diosgenin. The compound shows a purity of ≥70%. Detailed pharmacokinetic parameters are not extensively reported in publicly available sources. The compound is typically stored at -20°C. Further ADME studies are needed to fully characterize its pharmacokinetic profile. The compound is for research purposes.
|
| Toxicity/Toxicokinetics |
Toxicology data for Neodiosgenin are limited in publicly available sources. As a natural product, potential effects on lipid metabolism should be considered. The compound is for research use only and not intended for human therapeutic applications. Standard safety pharmacology and toxicology studies would be required for therapeutic development. The compound should be handled with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
Spirost-5-en-3-ol has been reported in yam, Chinese yam, and other organisms with available data. See also: diosgenin (note moved to); Yamogenin (note moved to).
Neodiosgenin (Yamogenin) is a research-grade steroidal sapogenin for studying LXR function and lipid metabolism. Its primary applications include metabolism research, liver disease research, and natural products research. The compound is not approved for clinical use and has not entered clinical trials. It is commercially available from various chemical suppliers for research purposes only. Its mechanism involves LXR antagonism and suppression of fatty acid synthesis. |
| Molecular Formula |
C27H42O3
|
|---|---|
| Molecular Weight |
414.63
|
| Exact Mass |
414.313
|
| CAS # |
512-06-1
|
| PubChem CID |
234096
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
527.1±50.0 °C at 760 mmHg
|
| Flash Point |
272.6±30.1 °C
|
| Vapour Pressure |
0.0±3.1 mmHg at 25°C
|
| Index of Refraction |
1.564
|
| LogP |
5.84
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
30
|
| Complexity |
746
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
WQLVFSAGQJTQCK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H42O3/c1-16-7-12-27(29-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(28)8-10-25(18,3)21(20)9-11-26(22,24)4/h5,16-17,19-24,28H,6-15H2,1-4H3
|
| Chemical Name |
5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-ol
|
| Synonyms |
Yamogenin; Neodiosgenin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~10 mg/mL (~24.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (2.41 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear EtOH stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (2.41 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (2.41 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4118 mL | 12.0589 mL | 24.1179 mL | |
| 5 mM | 0.4824 mL | 2.4118 mL | 4.8236 mL | |
| 10 mM | 0.2412 mL | 1.2059 mL | 2.4118 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
